Literature DB >> 9346426

Noninvasive quantitative measurements of regional cerebral blood flow using technetium-99m-L,L-ECD SPECT activated with acetazolamide: quantification analysis by equal-volume-split 99mTc-ECD consecutive SPECT method.

R Takeuchi1, H Matsuda, Y Yonekura, H Sakahara, J Konishi.   

Abstract

Resting- and acetazolamide (Acz)-activated-regional cerebral blood flow (rCBF) measurements were performed by consecutive single-photon emission computed tomography (SPECT) studies before and after Acz administration using equal-volume-split technetium-99m-L,L-ethyl cysteinate dimer. Quantitative rCBF images were converted from qualitative axial SPECT images by the application of Patlak plot graphical analysis with radionuclide angiography and Lassen's linearization correction. Total time span required for this study was 53 minutes. The unaffected side of 37 studies with unilateral vascular lesions and 45 studies without apparent vascular lesions showed 132 +/- 17% and 140 +/- 15% increase of mean CBF (mCBF), respectively, under Acz administration. Comparing these values, the Acz-activated rCBF increases of less-affected and affected hemispheres of 23 studies with bilateral vascular lesions (116 +/- 13% and 113 +/- 12%, respectively) was lower with high statistical significance (P < 0.001). For the other 20 cases, physiologic saline was administered instead of Acz. This group showed no changes in mCBF under placebo administration (after placebo/baseline; 100 +/- 6%). Acetazolamide-activated rCBF increase was recognized clearly and easily using quantitative images. This noninvasive method is easy to perform and may be helpful to detect regional abnormalities of hemodynamic reserve in cerebrovascular diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9346426     DOI: 10.1097/00004647-199710000-00003

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  7 in total

1.  Recovery of cerebrovascular reserves after stenting for symptomatic carotid artery stenosis.

Authors:  A Abe; T Ueda; M Ueda; S Nogoshi; Y Nishiyama; Y Katayama
Journal:  Interv Neuroradiol       Date:  2010-12-17       Impact factor: 1.610

2.  Usefulness of fully automated constant ROI analysis software for the brain: 3DSRT and FineSRT.

Authors:  Ryo Takeuchi; Tami Sengoku; Kaname Matsumura
Journal:  Radiat Med       Date:  2006-08

3.  Cerebral blood flow SPET in transient global amnesia with automated ROI analysis by 3DSRT.

Authors:  Ryo Takeuchi; Hiroshi Matsuda; Katsunori Yoshioka; Yoshiharu Yonekura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

4.  Improvement of signal-to-noise ratio using iterative reconstruction in a 99m Tc-ECD split-dose injection protocol.

Authors:  Takashi Yokoi; Hiroyuki Shinohara; Akihiro Takaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-24       Impact factor: 9.236

5.  Cerebral-perfusion-based single-photon emission computed tomography (SPECT) staging using NeuroGam® in patients with moyamoya disease.

Authors:  Jai-Hyuck Han; Young Seok Park; Won Hyoung Lee; Sung-Soo Koong; Kyung-Soo Min; Mou-Seop Lee; Young-Gyu Kim; Dong-Ho Kim; Kyung-Sil Yi; Sang-Hoon Cha
Journal:  Childs Nerv Syst       Date:  2015-12-11       Impact factor: 1.475

6.  Signal changes on magnetic resonance perfusion images with arterial spin labeling after carotid endarterectomy.

Authors:  Takafumi Shimogawa; Takato Morioka; Tetsuro Sayama; Sei Haga; Tomoaki Akiyama; Kei Murao; Yuka Kanazawa; Yoshihiko Furuta; Ayumi Sakata; Shuji Arakawa
Journal:  Surg Neurol Int       Date:  2016-12-21

7.  The cingulate island sign within early Alzheimer's disease-specific hypoperfusion volumes of interest is useful for differentiating Alzheimer's disease from dementia with Lewy bodies.

Authors:  Etsuko Imabayashi; Kota Yokoyama; Tadashi Tsukamoto; Daichi Sone; Kaoru Sumida; Yukio Kimura; Noriko Sato; Miho Murata; Hiroshi Matsuda
Journal:  EJNMMI Res       Date:  2016-09-13       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.